Roche Holding AG (XSWX:ROP) Marketable Securities: CHF9,894 Mil (As of Dec. 2025)


XSWX:ROP Roche Holding AG XSWX:ROP
77 GF Score
Price CHF340.60
GF Value CHF264.65
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Roche Holding AG Marketable Securities?

Roche Holding AG XSWX:ROP -0.26% 77 Marketable Securities is CHF9,894 Mil as of Dec. 2025. GuruFocus rates XSWX:ROP with a GF Score™ of 77/100 and a GF Value™ of CHF264.65 (Modestly Overvalued). The stock has 7 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Roche Holding AG's Marketable Securities for the quarter that ended in Dec. 2025 was CHF9,894 Mil.

Roche Holding AG's annual Marketable Securities increased from Dec. 2023 (CHF5,134 Mil) to Dec. 2024 (CHF10,342 Mil) but then declined from Dec. 2024 (CHF10,342 Mil) to Dec. 2025 (CHF9,894 Mil).

Roche Holding AG  (XSWX:ROP) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Roche Holding AG Marketable Securities Related Terms

Roche Holding AG Marketable Securities Historical Data

* Premium members only.

The historical data trend for Roche Holding AG's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Roche Holding AG Marketable Securities Chart

Roche Holding AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6,181.00 4,776.00 5,134.00 10,342.00 9,894.00

Roche Holding AG Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5,134.00 3,990.00 10,342.00 4,472.00 9,894.00
XSWX:ROP
77GF Score
Roche Holding AG XSWX:ROP
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Roche Holding AG Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of CHF9,894 Mil mean?
Roche Holding AG (XSWX:ROP) has a Marketable Securities of CHF9,894 Mil as of Dec. 2025. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Roche Holding AG and its competitors.
Is Roche Holding AG's Marketable Securities too high?
Roche Holding AG's current Marketable Securities is CHF9,894 Mil. Overall, Roche Holding AG has a GF Score™ of 77/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Roche Holding AG's Marketable Securities compare to LLY and JNJ?
Roche Holding AG's Marketable Securities of CHF9,894 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Drug Manufacturers company?
A good Marketable Securities depends on the Drug Manufacturers industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Roche Holding AG and its competitors. Roche Holding AG's current Marketable Securities is CHF9,894 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Roche Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Roche Holding AG (XSWX:ROP) is currently considered Modestly Overvalued. The stock's GF Value™ is CHF264.65, compared to a current price of CHF340.60 — trading 28.7% above its estimated fair value. The current Marketable Securities is CHF9,894 Mil. Roche Holding AG's overall GF Score™ is 77/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Roche Holding AG (XSWX:ROP), the current Marketable Securities is CHF9,894 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Roche Holding AG (XSWX:ROP) Overvalued in 2026?

Based on GuruFocus' analysis, Roche Holding AG stock appears to be overvalued. The current stock price of CHF340.60 is trading 28.7% above its estimated GF Value™ of CHF264.65. GuruFocus considers Roche Holding AG to be Modestly Overvalued.

Key valuation signals for XSWX:ROP:

  • Marketable Securities: CHF9,894 Mil
  • GF Value™: CHF264.65 vs. price of CHF340.60 (28.7% above fair value)
  • GF Score™: 77/100 with 7 warning signs

No single metric tells the full story. See the XSWX:ROP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Roche Holding AG Business Description

Address Grenzacherstrasse 124, Basel, CHE, 4070
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 40% of pharmaceutical sales, and centralized and point-of-care diagnostics for two-thirds of diagnostic-related sales.
77GF Score

Get the complete analysis for XSWX:ROP

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF340.60
Price
CHF264.65
GF Value